SEC Form 4

[]

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fenimore Christopher R. (Last) (First) (Middle)						2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN] 3. Date of Earliest Transaction (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)				
. ,		LL RIVER ROA	. ,			3. Date of Earliest Transaction (Month/Day/Year) 07/20/2020								VP Cont	roller			
(Street)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable							
. ,	TOWN N										Line) X Form filed by One Reporting Person Form filed by More than One Reporting							
(City)	(5								Person									
		Tal	ble I - N	lon-Deriv	vative	Sec	urities Ac	cquire	d, D	isposed o	f, or B	eneficial	ly Owned					
1. Title of Security (Instr. 3)			2. Transact Date (Month/Day		Execu if any	A. Deemed xecution Date, any Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of			5. Amou Securiti Benefic Owned Reporte	es F ially (I Following (I		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code		v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s) and 4)						
Common	Stock			07/20/2	020			M ⁽¹⁾		10,000	Α	\$179.1	3 25	,277	D			
Common	Stock			07/20/2	020			F ⁽¹⁾		6,291	D	\$655.5	7 18	,986	D			
Common	Stock			07/20/2	020			М		2,224	Α	\$52.03	21	,210	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		216	D	\$636.56	(2) 20	,994	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		154	D	\$637.88	(3) 20	,840	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		306	D	\$638.51	(4) 20	,534	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		75	D	\$639.64	(5) 20	,459	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		113	D	\$640.6	1 20	,346	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		855	D	\$641.58	(6) 19	,491	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		676	D	\$642.39	(7) 18	,815	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		691	D	\$643.49	(8) 18	,124	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		303	D	\$644.57	⁽⁹⁾ 17	,821	D			
Common	Stock			07/21/2	020			S ⁽¹⁾		72	D	\$645.3	3 17	,749	D			
Common Stock			07/21/2020				S ⁽¹⁾ S ⁽¹⁾		155	D			,594	D				
Common	Stock			07/21/2020						82			9 17	,512	D			
Common	Stock			07/21/2	020	<u> </u>		S ⁽¹⁾		11	D	\$658	17	,501	D			
Common Stock												1,	432	I	By 401(k) Plan			
Common Stock												1,	897		By Trust ⁽¹¹⁾			
Common Stock												5	509	I	by 2017 GRAT			
Common Stock													2,	284	I	by 2018 GRAT		
			Table I							posed of, , convertil			Owned					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date (Month/Day/Year)				med on Date,	ed 4. n Date, Transaction Code (Instr.					cisable and ate	7. Title a of Secu Underly	and Amount rities ing ve Security	8. Price of Derivative Security (Instr. 5)	9. Number o derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownershi (Instr. 4)		
					Code	v	(A) (D)	Date Exerci	sable	Expiration Date	Amou or Numb of Title Share							

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 5. Number of Derivative Securites Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			vative urities uired or oosed O) (Instr.	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	/ (A) (D)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Incentive Stock Option (right to buy)	\$52.03	07/20/2020		М			2,224	(12)	12/16/2021	Common Stock	2,224	\$0.0	0	D	
Non- Qualified Stock Option (right to buy)	\$179.13	07/20/2020		M ⁽¹⁾			10,000	(13)	12/14/2022	Common Stock	10,000	\$0.0	13,500	D	

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

2. Represents volume-weighted average price of sales of 216 shares of Company stock on July 21, 2020 at prices ranging from \$636.56 to \$636.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price.

3. Represents volume-weighted average price of sales of 154 shares of Company stock on July 21, 2020 at prices ranging from \$637.79 to \$637.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price.

4. Represents volume-weighted average price of sales of 306 shares of Company stock on July 21, 2020 at prices ranging from \$638.44 to \$638.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price.

5. Represents volume-weighted average price of sales of 75 shares of Company stock on July 21, 2020 at prices ranging from \$639.22 to \$639.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price.

6. Represents volume-weighted average price of sales of 855 shares of Company stock on July 21, 2020 at prices ranging from \$641.00 to \$641.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price.

7. Represents volume-weighted average price of sales of 676 shares of Company stock on July 21, 2020 at prices ranging from \$642.25 to \$642.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price.

8. Represents volume-weighted average price of sales of 691 shares of Company stock on July 21, 2020 at prices ranging from \$643.00 to \$643.04. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price.

9. Represents volume-weighted average price of sales of 303 shares of Company stock on July 21, 2020 at prices ranging from \$644.32 to \$644.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price.

10. Represents volume-weighted average price of sales of 155 shares of Company stock on July 21, 2020 at prices ranging from \$646.71 to \$646.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price.

11. These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.

12. The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

13. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/**Christopher R. Fenimore 07/22/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.